← Back to Clinical Trials
Recruiting Phase 4 NCT03420339

NCT03420339 Stimulant Effects on Disruptive Behavior

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03420339
Status Recruiting
Phase Phase 4
Sponsor Matthew J O'Brien, PhD, BCBA-D
Condition Attention Deficit Hyperactivity Disorder
Study Type INTERVENTIONAL
Enrollment 10 participants
Start Date 2018-10-01
Primary Completion 2027-03-01

Eligibility & Interventions

Sex All sexes
Min Age 48 Months
Max Age 12 Years
Study Type INTERVENTIONAL
Interventions
Stimulant

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.

This trial targets 10 participants in total. It began in 2018-10-01 with a primary completion date of 2027-03-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this study is to determine the effects of stimulant medication on disruptive behavior, function, preference and choice; however, it is primarily methodological and will add to current research by establishing an effective evaluation of the impact of stimulant medication on these behaviors. Three behavior assessments for children and adolescents diagnosed with AD/HD who exhibit disruptive behavior will be conducted: 1. Preference assessments will be conducted to determine whether preference for social and nonsocial items and activities differs under medication and non-medication conditions. 2. Functional analyses will be conducted to determine whether stimulant medication has an effect on the frequency and function or purpose of disruptive behavior. 3. Choice assessments will be conducted to evaluate the impact of stimulant medication on impulse control/delay discounting. This study will be conducted in three phases. For each of the 5 to 10 participants there will be 8 total visits. The first 4 visits will entail a preference assessment, followed by a functional analysis. On visits 1 and 3, the participant will be asked to take his/her stimulant medication as is typically done; however, on visits 2 and 4, the participant will be asked to refrain from taking the medication. For visits 5-8, participants will continue to participate in preference assessments, but will also be presented with a choice arrangement with work and play. In the choice arrangement, participants will be given four work cards and four play cards that they can organize in any order. Work cards will be associated with a brief academic task and play cards will be associated with a brief play period using high-preferred toys/activities. On visits 5 and 7 the participant will be asked to take his or her stimulant medication as usual, while on visits 6 and 8 the participant will be asked to refrain from taking his or her medication.

Eligibility Criteria

Inclusion Criteria: 1. Participant must be a child or adolescent between the ages of 4 years, 0 months, and 13 years, 0 months (participants must not be older than 12 years, 11 months). 2. Participant must have a valid diagnosis of attention deficit/hyperactivity disorder (AD/HD). No specification of type (e.g., predominately inattentive type, predominately hyperactive-impulsive type, or combined type) will be necessary. 3. Participant must exhibit disruptive behavior, defined as one or more of the following: 1. physical or verbal aggression towards others: Hitting, kicking, biting, scratching, choking, spitting at, or throwing items at another person, and/or making insults, threats, or swearing at another person. 2. self-injury: Hitting self, biting self, banging head on an object/hard surface, pinching self, or scratching self with visual skin damage. 3. destruction: Damaging (or attempts to damage) personal or public property (e.g., breaking an object into two or more pieces, using an object to break other objects, ripping objects or parts of objects from walls, floors, or furniture, and denting cars, objects, or walls.) 4. noncompliance:Regular occurrence of verbal refusal (e.g., saying "no", "I don't want to", "I won't do it" or "not now") to any academic or non-academic request, and/or any response that does not match the delivered instruction within 30 seconds from the time the instruction was delivered. 5. tantrum:Crying (i.e., any vocalizations \[sounds or words\] accompanied by facial contraction with and without tears for any period of time) and/or screaming (occurrence of vocalizations above normal conversational volume for any period of time), with or without body flailing. 6. an active diagnosis of disruptive behavior disorder or oppositional defiant disorder. 4. Participant must already be prescribed a stimulant medication for the treatment of AD/HD symptoms and at an approved dose for age. Exclusion Criteria: 1. a diagnosis of autism, conduct disorder, or intellectual disability in the moderate, severe or profound range. 2. prescribed or taking a stimulant dosage outside of recommended therapeutic range.

Contact & Investigator

Central Contact

Matthew J O'Brien, PhD

✉ matthew-j-obrien@uiowa.edu

📞 319.384.9827

Principal Investigator

Matthew J O'Brien, PhD

PRINCIPAL INVESTIGATOR

University of Iowa

Frequently Asked Questions

Who can join the NCT03420339 clinical trial?

This trial is open to participants of all sexes, aged 48 Months or older, up to 12 Years, studying Attention Deficit Hyperactivity Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT03420339 trial and what does that mean for participants?

Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.

Is NCT03420339 currently recruiting?

Yes, NCT03420339 is actively recruiting participants. Contact the research team at matthew-j-obrien@uiowa.edu for enrollment information.

Where is the NCT03420339 trial being conducted?

This trial is being conducted at Iowa City, United States.

Who is sponsoring the NCT03420339 clinical trial?

NCT03420339 is sponsored by Matthew J O'Brien, PhD, BCBA-D. The principal investigator is Matthew J O'Brien, PhD at University of Iowa. The trial plans to enroll 10 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology